aibioSIGA SIGA Technologies Inc.
SIGA Technologies (SIGA) news
Top story · Aug 6, 2026 · Company press release
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026 • $37 Million of TPOXX Sales Generated in the Second Quarter • Corporate Update Conference Call Today at 4:30
Latest SIGA Technologies news
We have not published a story on SIGA Technologies yet. When there is news, it will appear here.
What SIGA Technologies does
SIGA Technologies is a commercial-stage pharmaceutical company. Its lead product, TPOXX (oral tecovirimat), is an antiviral for the treatment of human smallpox, and the company sells it to the U.S. Government and international governments. SIGA also sells the intravenous formulation, IV TPOXX, to the U.S. Government. The FDA approved oral TPOXX on July 13, 2018 and IV TPOXX on May 18, 2022, and oral TPOXX also has approvals from the EMA, Health Canada, the UK's MHRA and Japan's PMDA. In July 2025 the EMA's human medicines committee opened a referral over effectiveness in treating mpox, and SIGA expects a recommendation to withdraw the mpox indication while smallpox, cowpox and vaccinia complications are maintained. The company is targeting a supplemental NDA for a smallpox post-exposure prophylaxis indication within the next twelve months. Its U.S. Government contracts include the 19C BARDA Contract, which as of December 31, 2025 contemplates up to approximately $630 million of payments.
| Product or program | What it is | Stage |
|---|---|---|
| TPOXX (oral tecovirimat) | Antiviral for the treatment of smallpox, also approved for mpox in some markets | approved in the US |
| IV TPOXX | Intravenous formulation of TPOXX for smallpox | approved in the US |
SIGA Technologies annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $94.6 million | $138.7 million |
| Research and development | $20.0 million | $12.3 million |
| Net income (loss) | $23.3 million | $59.2 million |
| Cash from operations | $43.5 million | $48.8 million |
| Cash and equivalents | $155.0 million | $155.4 million |
Questions about SIGA Technologies
What is the ticker symbol of SIGA Technologies?
SIGA Technologies Inc. trades under the ticker SIGA on NASDAQ.
Where is SIGA Technologies listed?
SIGA Technologies Inc. is listed on NASDAQ.
What is the SEC CIK of SIGA Technologies?
The SEC Central Index Key (CIK) for SIGA Technologies Inc. is 1010086. Its filings are on SEC EDGAR.
How many shares does SIGA Technologies have outstanding?
71,849,716 shares as of 2026-07-24, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is SIGA Technologies listed under?
Our directory records SIGA Technologies Inc. under United States.
What does SIGA Technologies do?
Our directory classifies SIGA Technologies Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of SIGA Technologies?
The ISIN recorded for SIGA Technologies Inc. is US8269171067.
Does aibio.space cover SIGA Technologies?
aibio.space lists SIGA Technologies Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is SIGA Technologies incorporated?
SEC records list its state or country of incorporation as DE.
What does SIGA Technologies develop?
SIGA Technologies is a commercial-stage pharmaceutical company. Its lead product, TPOXX (oral tecovirimat), is an antiviral for the treatment of human smallpox, and the company sells it to the U.S. Government and international governments.
What is TPOXX (oral tecovirimat) from SIGA Technologies?
TPOXX (oral tecovirimat): Antiviral for the treatment of smallpox, also approved for mpox in some markets Stage: approved in the US.
What is IV TPOXX from SIGA Technologies?
IV TPOXX: Intravenous formulation of TPOXX for smallpox Stage: approved in the US.
What was SIGA Technologies's revenue last year?
$94.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is SIGA Technologies profitable?
SIGA Technologies Inc. reported net income of $23.3 million for the fiscal year ended Dec 31, 2025, and generated $43.5 million of cash from operations, per its annual report to the SEC.
How much does SIGA Technologies spend on research and development?
$20.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
Investor discussion: SIGA Technologies
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
SEC filings and registration
- SEC name
- Siga Technologies Inc
- CIK
- 1010086
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- SIGA (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Accelerated filer
- Business address
- 31 EAST 62ND STREET, NEW YORK, NY, 10065
- Phone
- 212-672-9100
- Shares outstanding
- 71,849,716 as of 2026-07-24 (10-Q filed 2026-08-06)
- Former names
- SIGA PHARMACEUTICALS INC
Recent filings
Listing details
- Company
- SIGA Technologies Inc.
- Ticker
- SIGA
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US8269171067
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction